Votre sélection est vide.
Sélectionnez des ETF pour les comparer les uns aux autres.
Ajoutez un ETF à la sélection en le sélectionnant dans le sélecteur d’ETF ou sous « Comparer » sous le profil de l’ETF.
BioMarin Pharmaceutical
ISIN US09061G1013
|WKN 924801
Market cap (in EUR)
9 833 M
Country
États-Unis
Sector
Santé
Dividend yield
0,00%
Overview
Quote
Description
BioMarin Pharmaceutical, Inc. se consacre au développement et à la commercialisation de thérapies destinées aux personnes atteintes de maladies et d'affections rares graves et potentiellement mortelles. Ses produits en cours de développement comprennent le Valoctocogene roxaparvovec, le Vosoritide et le BMN 307. La société a été fondée par John C. Klock, Christopher M. Starr et Grant W. Denison le 21 mars 1997, et son siège social se trouve à San Rafael, en Californie.
Santé Produits biopharmaceutiques Produits biopharmaceutiques systémiques États-Unis
Chart
Financials
Key metrics
| Market capitalisation, EUR | 9 833 M |
| EPS, EUR | 1,58 |
| P/B ratio | 1,8 |
| P/E ratio | 32,4 |
| Dividend yield | 0,00% |
Compte de résultat (2025)
| Revenue, EUR | 2 874 M |
| Net income, EUR | 309 M |
| Profit margin | 10,76% |
Quel ETF contient BioMarin Pharmaceutical ?
Il y a 13 ETF qui contiennent BioMarin Pharmaceutical. Tous ces ETF sont énumérés dans le tableau ci-dessous. L’ETF ayant la plus grande pondération de BioMarin Pharmaceutical est le iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
Performance
Returns overview
| YTD | -1.77% |
| 1 month | -0.71% |
| 3 months | +13.53% |
| 6 months | +9.99% |
| 1 year | -21.68% |
| 3 years | -43.17% |
| 5 years | -22.85% |
| Since inception (MAX) | -40.66% |
| 2025 | -19.79% |
| 2024 | -27.75% |
| 2023 | -8.14% |
| 2022 | +20.96% |
Monthly returns in a heat map
Risk
Risk metrics in this section:
- Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
- Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
- Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.
Risk overview
| Volatility 1 year | 37.65% |
| Volatility 3 years | 32.58% |
| Volatility 5 years | 31.79% |
| Return per risk 1 year | -0.58 |
| Return per risk 3 years | -0.53 |
| Return per risk 5 years | -0.16 |
| Maximum drawdown 1 year | -34.70% |
| Maximum drawdown 3 years | -51.92% |
| Maximum drawdown 5 years | -59.31% |
| Maximum drawdown since inception | -68.14% |
Rolling 1 year volatility
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.